Publication: Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
This research article, published in PLoS ONE, provides a summary of the prognostic indicators of disease progression in Duchenne muscular dystrophy (DMD)
Understand the approach taken to systematically review the available data to determine prognostic indicators of disease progression in DMD
Review the wealth of data available for each prognostic indicator
Learn which prognostic indicators are considered ‘core’ with regard to determining disease progression outcomes in DMD
Ferizovic N, Summers J, Zárate IBO, et al. PLoS ONE. 2022;17(3):e0265879
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200168 | May 2022
Sign in or register to access exclusive content on this site